An essential resource for R&D professionals and clinicians with an interest in biologic therapies.
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.
BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.
《Biodrugs》是一本由ADIS INT LTD出版商出版的專業醫學期刊，該刊創刊于1994年，刊期Bimonthly，該刊已被國際權威數據庫SCIE收錄。在中科院最新升級版分區表中，該刊分區信息為大類學科：醫學 3區，小類學科：免疫學 3區；腫瘤學 3區；藥學 3區；在JCR（Journal Citation Reports）分區等級為Q1。該刊發文范圍涵蓋免疫學等領域，旨在及時、準確、全面地報道國內外免疫學工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等，促進學術交流，鼓勵學術創新。2021年影響因子為7.744，平均審稿速度>12周，或約稿。
| 大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
| 醫學 | 3區 | PHARMACOLOGY & PHARMACY 藥學 IMMUNOLOGY 免疫學 ONCOLOGY 腫瘤學 | 2區 3區 3區 | 否 | 否 |
| JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
| Q1 | ONCOLOGY | Q1 | 7.744 |
| PHARMACOLOGY & PHARMACY | Q1 | ||
| IMMUNOLOGY | Q1 |
| 影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
| 7.744 | 60 | 45.83% | 61.70% | 未開放 | >12周，或約稿 |
投稿咨詢
課題、SCI/EI/SSCI怎么寫？